Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class - Global Industry Analysis & Forecast to 2027
Published On : April 2019 Pages : 167 Category: Pharma & Healthcare Report Code : HC043430
Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class (Calcium Channel Blocker, Stool Softener, Opioid Analgesic, Anticonvulsant, Osmotic Agent/Diuretic, Other Drugs) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The Aneurysmal Subarachnoid Hemorrhage Drugs Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Aneurysmal subarachnoid hemorrhage is a sort of stroke, which is occurs due to bleeding in the subarachnoid gap of the brain. The main cause behind aneurysmal subarachnoid discharge incorporates mind aneurysm, arteriovenous mutation, or head damage. Change in ways of life, for example, smoking and liquor utilization increment the hazard for aSAH, just as ascend in aged populace are the main considerations that add to the development of the market.
Drivers and Restraints
The main factors that drive the development of the worldwide aneurysmal subarachnoid drain drugs showcase incorporate flood in geriatric populace and high commonness of populace experiencing hypertension. Besides, lifestyle habits, for example, liquor utilization and smoking increment the danger of aSAH, which thus push the market development. Nonetheless, the related reactions of medications and drug taken amid the treatment of aneurysmal subarachnoid discharge limit the market development.
Regional Insights
The Asia-Pacific market is anticipated to develop at the most astounding CAGR of 5.5% amid the estimate time frame, attributable to ascend in awareness about the treatment of aneurysmal subarachnoid discharge in the human services industry and flood in consumptions in developing markets, for example, India and China to oblige the neglected restorative needs.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Edge Therapeutics, Inc
- Mylan N.V.
- Purdue Pharma L.P
- Sun Pharmaceutical Industries Ltd
- Arbor Pharmaceuticals Inc
- Johnson & Johnson
- Orexo AB
- Pharmaxis, Ltd
- Teva Pharmaceutical Industries Ltd
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Drug Class, Estimates and Forecast, 2017-2027 ($Million)
o Stool Softener
o Calcium Channel Blocker
o Opioid Analgesic
o Osmotic Agent
o Anticonvulsant
o Other Drugs
· Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Key Players
o Edge Therapeutics, Inc.,
o Arbor Pharmaceuticals Inc.
o Orexo AB
o Mylan N.V.
o Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.).
o Sun Pharmaceutical Industries Ltd
o Pharmaxis, Ltd.
o Purdue Pharma L.P.
o Pfizer Inc.
· Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Country
o U.S. Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Canada Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Europe
§ Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Country
o Germany Aneurysmal Subarachnoid Hemorrhage Drugs Market
o UK Aneurysmal Subarachnoid Hemorrhage Drugs Market
o France Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Russia Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Italy Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Asia-Pacific
§ Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Country
o China Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Japan Aneurysmal Subarachnoid Hemorrhage Drugs Market
o South Korea Aneurysmal Subarachnoid Hemorrhage Drugs Market
o India Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market
o South America
§ South America Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Columbia Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Middle East and Africa
§ Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Market
o UAE Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Nigeria Aneurysmal Subarachnoid Hemorrhage Drugs Market
o South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market
o Rest of MEA Aneurysmal Subarachnoid Hemorrhage Drugs Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.3. SWOT Analysis
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Drug Class
5.1. Introduction
5.2. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Market Share by Drug Class (2017-2027)
5.2.1. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Revenue Share by Drug Class (2017-2027)
5.3. Stool Softener
5.3.1. Global Stool Softener Revenue and Growth Rate (2017-2027)
5.4. Calcium Channel Blocker
5.4.1. Global Calcium Channel Blocker Revenue and Growth Rate (2017-2027)
5.5. Opioid Analgesic
5.5.1. Global Opioid Analgesic Revenue and Growth Rate (2017-2027)
5.6. Osmotic Agent
5.6.1. Global Osmotic Agent Revenue and Growth Rate (2017-2027)
5.7. Anticonvulsant
5.7.1. Global Anticonvulsant Revenue and Growth Rate (2017-2027)
5.8. Other Drugs
5.8.1. Global Other Drugs Revenue and Growth Rate (2017-2027)
6. Aneurysmal Subarachnoid Hemorrhage Drugs Market, By Region
6.1. Introduction
6.2. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Market Share by Regions
6.2.1. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Regions (2017-2027)
6.3. North America Aneurysmal Subarachnoid Hemorrhage Drugs by Countries
6.3.1. North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2027)
6.3.2. North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2027)
6.3.3. United States
6.3.3.1. United States Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.4. Canada
6.3.4.1. Canada Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.3.5. Mexico
6.3.5.1. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4. Europe Aneurysmal Subarachnoid Hemorrhage Drugs by Countries
6.4.1. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2027)
6.4.2. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2027)
6.4.3. Germany
6.4.3.1. Germany Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.4. France
6.4.4.1. France Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.5. UK
6.4.5.1. UK Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.6. Russia
6.4.6.1. Russia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.7. Italy
6.4.7.1. Italy Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.4.8. Rest of Europe
6.4.8.1. Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs by Countries
6.5.1. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2027)
6.5.2. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2027)
6.5.3. China
6.5.3.1. China Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.4. Japan
6.5.4.1. Japan Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.5. Korea
6.5.5.1. Korea Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.6. India
6.5.6.1. India Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.7. Southeast Asia
6.5.7.1. Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.5.8. Rest of Asia-Pacific
6.5.8.1. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.6. South America Aneurysmal Subarachnoid Hemorrhage Drugs by Countries
6.6.1. South America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2027)
6.6.2. South America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2027)
6.6.3. Brazil
6.6.3.1. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.4. Argentina
6.6.4.1. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.5. Columbia
6.6.5.1. Columbia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.6.6. Rest of South America
6.6.6.1. Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7. Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs by Countries
6.7.1. Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2027)
6.7.2. Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2027)
6.7.3. Saudi Arabia
6.7.3.1. Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.4. United Arab Emirates
6.7.4.1. United Arab Emirates Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.5. Egypt
6.7.5.1. Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.6. Nigeria
6.7.6.1. Nigeria Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.7. South Africa
6.7.7.1. South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.8. Turkey
6.7.8.1. Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
6.7.9. Rest of Middle East and Africa
6.7.9.1. Rest of Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7. Company Profiles
7.1. Edge Therapeutics, Inc.,
7.1.1. Business Overview
7.1.2. Service Portfolio
7.1.3. Strategic Developments
7.1.4. Financial Overview
7.2. Arbor Pharmaceuticals Inc.
7.2.1. Business Overview
7.2.2. Service Portfolio
7.2.3. Strategic Developments
7.2.4. Financial Overview
7.3. Orexo AB
7.3.1. Business Overview
7.3.2. Service Portfolio
7.3.3. Strategic Developments
7.3.4. Financial Overview
7.4. Mylan N.V.
7.4.1. Business Overview
7.4.2. Service Portfolio
7.4.3. Strategic Developments
7.4.4. Financial Overview
7.5. Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.).
7.5.1. Business Overview
7.5.2. Service Portfolio
7.5.3. Strategic Developments
7.5.4. Financial Overview
7.6. Sun Pharmaceutical Industries Ltd
7.6.1. Business Overview
7.6.2. Service Portfolio
7.6.3. Strategic Developments
7.6.4. Financial Overview
7.7. Pharmaxis, Ltd.
7.7.1. Business Overview
7.7.2. Service Portfolio
7.7.3. Strategic Developments
7.7.4. Financial Overview
7.8. Purdue Pharma L.P.
7.8.1. Business Overview
7.8.2. Service Portfolio
7.8.3. Strategic Developments
7.8.4. Financial Overview
7.9. Pfizer Inc.
7.9.1. Business Overview
7.9.2. Service Portfolio
7.9.3. Strategic Developments
7.9.4. Financial Overview
8. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Competition, by Manufacturer
8.1. Global Aneurysmal Subarachnoid Hemorrhage Drugs Financial Overview by Manufacturer (2017-2017)
8.2. Global Aneurysmal Subarachnoid Hemorrhage Drugs Price By Region (2017-2017)
8.3. Top 5 Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturer Market Share
8.4. Market Competition Trend
9. Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.1. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast by Regions (2017-2027)
9.2.1. North America Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.1.1. United States Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.1.2. Canada Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.1.3. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.2. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.2.1. Germany Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.2.2. France Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.2.3. UK Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.2.4. Russia Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.2.5. Italy Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.3. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.3.1. China Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.3.2. Japan Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.3.3. Korea Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.3.4. India Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.4. South America Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.4.1. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.4.2. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.4.3. Columbia Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.4.4. Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.5. Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.5.3. Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.5.4. Nigeria Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.5.5. South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.5.6. Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2017-2027)
9.3. Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast by Drug Class (2017-2027)
9.3.1. Aneurysmal Subarachnoid Hemorrhage Drugs Forecast by Drug Class (2017-2027)
9.3.2. Aneurysmal Subarachnoid Hemorrhage Drugs Market Share Forecast by Drug Class (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Revenue Share by Drug Class (2017-2018)
Figure Global Stool Softener Revenue and Growth Rate (2017-2018)
Figure Global Calcium Channel Blocker Revenue and Growth Rate (2017-2018)
Figure Global Opioid Analgesic Revenue and Growth Rate (2017-2018)
Figure Global Osmotic Agent Revenue and Growth Rate (2017-2018)
Figure Global Anticonvulsant Revenue and Growth Rate (2017-2018)
Figure Global Other Drugs Revenue and Growth Rate (2017-2018)
Table Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Regions (2017-2018)
Figure North America Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2018)
Figure North America Aneurysmal Subarachnoid Hemorrhage Drugs by Countries (2017-2018)
Figure North America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure United States Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Canada Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Aneurysmal Subarachnoid Hemorrhage Drugs by Countries (2017-2018)
Figure Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Germany Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure France Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure UK Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Russia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Italy Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs by Countries (2017-2018)
Figure Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure China Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Japan Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Korea Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure India Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure South America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2018)
Figure South America Aneurysmal Subarachnoid Hemorrhage Drugs by Countries (2017-2018)
Figure South America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Columbia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs by Countries (2017-2018)
Figure Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Nigeria Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Edge Therapeutics, Inc., Aneurysmal Subarachnoid Hemorrhage Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Arbor Pharmaceuticals Inc. Aneurysmal Subarachnoid Hemorrhage Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Mylan N.V. Aneurysmal Subarachnoid Hemorrhage Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Teva Pharmaceutical Industries Ltd. (Cephalon, Inc.). Aneurysmal Subarachnoid Hemorrhage Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sun Pharmaceutical Industries Ltd Aneurysmal Subarachnoid Hemorrhage Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pharmaxis, Ltd. Aneurysmal Subarachnoid Hemorrhage Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Purdue Pharma L.P. Aneurysmal Subarachnoid Hemorrhage Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pfizer Inc. Aneurysmal Subarachnoid Hemorrhage Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Share by Manufacturer
Figure Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue and Market Share by Manufacturer
Table Global Aneurysmal Subarachnoid Hemorrhage Drugs Price by Region (2017-2017)
Figure Top 5 Aneurysmal Subarachnoid Hemorrhage Drugs Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast by Regions (2018-2025)
Figure North America Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure United States Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Canada Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Germany Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure France Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure UK Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Russia Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Italy Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure China Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Japan Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Korea Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure India Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure South America Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Columbia Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Nigeria Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure South Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Aneurysmal Subarachnoid Hemorrhage Drugs Market Forecast (2018-2025)
Figure Global Aneurysmal Subarachnoid Hemorrhage Drugs Forecast by Drug Class (2018-2025)
Figure Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Share Forecast by Drug Class (2018-2025)
Figure Global Aneurysmal Subarachnoid Hemorrhage Drugs Forecast by Drug Class (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|